Skip to content
ApprovedFDA approved

L‑Carnitine

A supplement and a medicine, also used as a fat burner; it carries fatty acids into the cell's energy-producing part.

L-Carnitine vial

DETAILED OVERVIEW

What is L-Carnitine?

L-carnitine (L-Carnitine) is a substance the body also makes itself, from lysine and methionine, two amino acids. As a medicine it is approved to treat primary carnitine deficiency; as a supplement it is available without a prescription as capsules or a solution, while the injectable form needs a prescription. Athletes and people trying to lose weight use it as a fat burner.

In cells it acts as a carrier: it brings fatty acids into the mitochondria (the cell's energy-producing part), where they are burned. In studies, after prolonged use together with carbohydrate, the carnitine level in muscle rose two- to three-fold. Taken by mouth in larger amounts, it often causes diarrhea, nausea and a fishy body odor. Together with blood thinners such as warfarin it can raise the risk of bleeding. Only the L-form is useful; the D-form may be toxic to the heart, so a mixed (D,L) product can be dangerous. It is not on the WADA prohibited list, but the German anti-doping agency monitors very large amounts given intravenously.

Mechanism of action

Long-chain fatty acid CoA-mediated mitochondrial shuttle (CPT-I/II), rate-limiting step of β-oxidation

Half-life

~15 hours (parent compound), muscle loading steady-state 3-4 weeks chronic

Onset

Oral 1-2 hours (low bioavailability ~15%); IM/SC 30-60 minutes (100% bioavailability)

Legal status

Medicine (for carnitine deficiency) and dietary supplement; not banned

Data console

Lab data

Androgenic:AnabolicN/A (not an AAS, quaternary ammonium compound)
AR bindingNo nuclear receptor binding; CPT-I + CPT-II enzymatic…
Active half-life~15 óra
Detection windowWADA-akkreditált LC-MS/MS NEM standard test, chronic high-dose ~1-2 hét
AromatizationNem aromatizál (nem szteroid hatóanyag – kvaterner ammónium-vegyület).
HepatotoxicityAlacsony – endogén-szintetizált, krónikus oral <3 g/nap hepatikusan biztonságos.

Safety

Side effects, stop signs, contraindications

Side effects · 8

  • Gastrointestinal upset: diarrhea, nausea, abdominal cramps, heartburn, especially at oral doses >2 g/day (the most common, dose-dependent side effect).
  • Fishy body odor (trimethylaminuria-like): gut bacteria produce trimethylamine from carnitine, causing a fishy smell in sweat, breath and urine, typically at >2 g/day.
  • Elevated serum TMAO (trimethylamine-N-oxide) with chronic high-dose use (>2 g/day, 6+ months); an atherosclerosis risk-marker, though its causal role is debated (Koeth 2013 vs Yancey 2018).
  • Injectable form (IM/SC): painful injection (PIP), local irritation from the quaternary-ammonium vehicle, rarely sterile abscess or transient local redness and warmth.
  • Rare allergic/histamine-release reaction with parenteral dosing (flushing, itching, hypotension); a 0.5 g test dose is advised for the first IM/SC injection.
  • Thyroid interaction: carnitine inhibits peripheral T4-to-T3 conversion, which in patients treated for hypothyroidism may worsen symptoms or require levothyroxine dose adjustment (Benvenga 2001).
  • Warfarin/anticoagulant interaction: chronic carnitine dosing can raise INR, increasing bleeding risk; INR monitoring is required (Martinez 2007).
  • Rarely restlessness, mild stimulant-like feeling and sleep disturbance at higher doses; through lowering of the seizure threshold, increased seizure frequency has been reported in predisposed individuals.

Contraindications · 7

  • Seizure disorder (epilepsy) or a condition predisposing to seizures: carnitine may rarely lower the seizure threshold and increase seizure frequency, so caution is required.
  • Severe renal failure / dialysis (ESRD): dose adjustment is needed due to reduced renal clearance, and D,L-carnitine (racemic OTC) must be strictly avoided because of the D-isomer's cardiotoxic/myasthenic risk.
  • Concurrent warfarin or other coumarin anticoagulant: due to the risk of elevated INR and bleeding, only with close INR monitoring under medical supervision.
  • Treated hypothyroidism (on levothyroxine): carnitine weakens the peripheral action of thyroid hormone, which can reduce treatment efficacy; dose monitoring is required.
  • Known hypersensitivity to L-carnitine (or any component of the formulation); for the parenteral form, a prior histamine/allergic reaction to injection.
  • Pregnancy and breastfeeding without an Rx indication: supplement-dose is FDA category B, but high-dose IM/SC parenteral use is not recommended without medical indication.
  • Overlap with carnitine supplementation during valproate therapy: valproate can cause carnitine deficiency and is often therapeutically supplemented, so cycle-level supplementation only in consultation with the treating physician.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about L‑Carnitine?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.